![]() |
市場調査レポート
商品コード
1709427
日本の血管アクセスデバイス市場:製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測、2019年~2033年Japan Vascular Access Devices Market Assessment, By Product Type, By Application, By End-user, By Region, Opportunities and Forecast, FY2019-FY2033F |
||||||
カスタマイズ可能
|
日本の血管アクセスデバイス市場:製品タイプ別、用途別、エンドユーザー別、地域別、機会、予測、2019年~2033年 |
出版日: 2025年04月21日
発行: Market Xcel - Markets and Data
ページ情報: 英文 121 Pages
納期: 3~5営業日
|
日本の血管アクセスデバイスの市場規模は、2026年~2033年の予測期間中に6.14%のCAGRで拡大し、2025年の3億8,844万米ドルから2033年には5億8,942万米ドルに成長すると予測されています。日本の血管アクセスデバイス市場は、がんや腎臓病などの慢性疾患の有病率の上昇により、日本のヘルスケア環境全体で血管アクセス器具の使用が増加しているため、大きく成長しています。政府のヘルスケア改革と病院のインフラ整備は、先進血管技術の採用をさらに促進しています。さらに、国内メーカーが安全設計の耐感染性カテーテルに注力することで、急性期医療と長期療養の両環境における市場の成長が加速しています。
例えば、日本の厚生労働省は2024年12月1日にDVT用血栓除去システム「クロットトリーバー」の保険償還を承認しました。この声明は、医薬品医療機器総合機構(PMDA)が2023年12月にクロットトリーバー・システムを承認した後のものです。厚生労働省は、クロットトリーバーの特殊な作用機序により、DVT患者において壁から壁まで完全に血栓を除去することができるため、これまでのカテーテルを用いた治療法とは異なる新たな機能区分を設定しました。
当レポートでは、日本の血管アクセスデバイス市場について調査し、市場の概要とともに、製品タイプ別、用途別、エンドユーザー別、地域別動向、および市場に参入する企業のプロファイルなどを提供しています。
Japan vascular access devices market is projected to witness a CAGR of 6.14% during the forecast period FY2026-FY2033, growing from USD 388.44 million in FY2025 to USD 589.42 million in FY2033. Japan market for dermal fillers has grown significantly due to rising prevalence of chronic conditions such as cancer and renal disease is prompting increased use of vascular access devices across Japanese healthcare settings. Government healthcare reforms and hospital infrastructure upgrades are further facilitating the adoption of advanced vascular technologies. Additionally, local manufacturers' focus on safety-engineered, infection-resistant catheters is accelerating market growth in both acute and long-term care environments.
For example, the Japanese Ministry of Health, Labor and Welfare (MHLW) approved the ClotTriever Thrombectomy System for DVT for national reimbursement on December 1, 2024, according to a statement released today by Inari Medical, Inc., a medical device company dedicated to treating and improving the lives of patients with venous and other vascular diseases. This statement comes after the Pharmaceuticals and Medical Devices Agency (PMDA) approved the ClotTriever system in December 2023. MHLW established a new functional category distinct from previous catheter-based therapies because of ClotTriever's special mode of action for total, wall-to-wall thrombus elimination in patients with DVT.
Rising Geriatric Population and Prevalence of Chronic Conditions Driving Market Growth
Japan has one of the highest proportions of elderly individuals globally, with more than 29% of its population aged 65 or older. This aging demographic is more susceptible to chronic diseases such as cardiovascular disorders, diabetes, and cancer, which often require repeated intravenous treatments, thereby boosting the demand for vascular access devices. The increase in long-term hospital stays and the need for regular drug or fluid administration further propel the market. Additionally, age-related complications increase the likelihood of conditions like kidney failure, which often require dialysis through central vascular access. These factors collectively support the growing adoption of vascular access devices in Japan's healthcare system. For instance, according to Japan's Ministry of Internal Affairs and Communications, as of 2023, seniors (65+) made up 29.1% of the total population, highlighting the pressing need for chronic disease management solutions.
Technological Advancements and Focus on Infection Control in Hospitals Fueling Growth
Japanese healthcare facilities are placing greater emphasis on adopting technologically advanced vascular access devices that minimize infection risk and improve efficiency. Innovations in catheter coatings, antimicrobial materials, and securement devices have significantly reduced complications such as catheter-related bloodstream infections (CRBSIs). Japan's hospitals, known for their high standards of care and patient safety, are actively integrating smart vascular access technologies, such as ultrasound-guided placement and needle-free connectors, to enhance clinical outcomes. Moreover, post-pandemic hygiene awareness has accelerated the shift toward disposable and safer vascular access solutions. These trends are boosting the penetration of vascular access devices in both public and private healthcare settings. For example, in April 2024, Nipro partnered with Haselmeier to introduce the PiccoJect, a patient-centric autoinjector designed for 1 mL long and 2.25 mL, pre-filled syringes. The device was showcased at CPHI Japan in Tokyo, which marks Nipro's commitment to innovative drug delivery solutions.
Increasing Demand for Peripheral Vascular Access Devices for Short-Term Use
Peripheral vascular access devices are witnessing a significant rise in adoption across Japan due to their widespread use in short-term therapies such as drug infusions, fluid administration, and nutritional support. These devices, including peripheral intravenous (PIV) catheters, are easy to insert, cost-effective, and less invasive compared to central vascular access devices, making them ideal for outpatient departments, emergency care, and routine medical interventions. The increasing number of outpatient surgeries, homecare treatments, and emergency admissions in Japan's aging healthcare infrastructure is supporting the demand for these products. Additionally, patient preference for minimally invasive and shorter treatment durations aligns with the utility of peripheral devices. Healthcare providers in Japan are also investing in newer-generation safety-engineered PIV catheters that minimize needlestick injuries and infection risks, enhancing procedural outcomes and staff safety. These developments are collectively contributing to the growing adoption of peripheral vascular access devices in Japan's evolving clinical care landscape. In March 2024, B. Braun Aesculap Japan introduced "Introcan Safety(R) 2 IV Catheter," which features enhanced safety mechanisms to reduce needlestick injuries and is tailored for peripheral access in short-term treatments.
Future Market Scenario (FY2026 - FY2033F)
The Japan vascular access devices market is poised for steady growth in the coming years, driven by an aging population, rising chronic disease burden, and an evolving healthcare system that emphasizes minimally invasive treatments. As hospitals and clinics increasingly adopt advanced vascular access technologies to reduce infection risks and improve patient outcomes, demand for both central and peripheral access devices is expected to rise. The market is also likely to benefit from local innovation, government support for digital healthcare, and a growing preference for home-based care. Continuous R&D and product upgrades will further enhance market penetration across urban and rural settings.
Key Players Landscape and Outlook
Key players in the vascular access devices industry utilize strategies such as mergers, acquisitions, partnerships, and new product launches to improve their services and competitiveness. Such efforts will propel significant growth in the market, allowing big-cap industry players to increase their presence and, therefore, find new opportunities in this market.
For instance, In January 2025, Nipro announced the international sales launch of the DIAMAX WOW Single Patient Dialysis Machines. This product introduction shows Nipro's dedication for advancing the dialysis technology and improving patient care.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.